Human Cytomegalovirus: From Molecular Pathogenesis to Therapeutic Innovations

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 496

Special Issue Editors


E-Mail Website
Guest Editor
Infinity, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291, CNRS UMR5051, Toulouse University, CEDEX 3, 31024 Toulouse, France
Interests: human cytomegalovirus; glioblastoma; targets; biomarkers; biotherapies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
UMR 1092 RESINFIT, Limoges University, BP 23204, 87032 Limoges, France
Interests: human cytomegalovirus; antiviral targets; helicase–primase complex

Special Issue Information

Dear Colleagues,

Human cytomegalovirus (HCMV) or human herpesvirus 5 is a ubiquitous herpesvirus that infects a large proportion of the global population. It remains asymptomatic in most healthy individuals, but it is one of the most important causes of complications in immunocompromised patients (patients with AIDS and solid organ transplant or hematopoietic stem cell transplant recipients) and those with congenital infections. HCMV could also represent an interesting target for treatment to limit the progression of glioblastoma, a highly aggressive tumor.

HCMV encodes a variety of gene products that regulate a wide array of cellular and immune pathways. However, there are still significant gaps in our understanding of how these gene products contribute to viral persistence and pathogenesis. Furthermore, the currently used antivirals, for which efficacy has been demonstrated, exhibit significant toxicity, and, most importantly, numerous resistances to these treatments have emerged. Therefore, it is essential to identify new therapeutic targets.

This Special Issue will focus on recent advances in understanding the pathogenesis of HCMV, its interactions with the host cells and new developments in therapeutic strategies.

Dr. Gaëtan Ligat
Dr. Alexia Damour
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human cytomegalovirus
  • therapeutic strategies and vaccines
  • glioblastoma
  • congenital infection
  • immunocompromised

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 339 KB  
Review
Exploring pUS27: Insights into Its Role in HCMV Pathogenesis and Potential for Antiviral Strategies
by Gage M. Connors and Juliet V. Spencer
Pathogens 2025, 14(10), 993; https://doi.org/10.3390/pathogens14100993 - 1 Oct 2025
Viewed by 261
Abstract
Human cytomegalovirus (HCMV) is a complex pathogen that encodes a diverse array of proteins essential for its survival and replication within host organisms. Among these proteins, a noteworthy group comprises four chemokine-like G protein-coupled receptors (cellular GPCRs), which play pivotal roles in the [...] Read more.
Human cytomegalovirus (HCMV) is a complex pathogen that encodes a diverse array of proteins essential for its survival and replication within host organisms. Among these proteins, a noteworthy group comprises four chemokine-like G protein-coupled receptors (cellular GPCRs), which play pivotal roles in the virus’s evasion of the host immune response and the establishment of persistent infections. Of particular interest is pUS28, recognized as one of the most extensively studied viral GPCRs (vGPCRs). This receptor has attracted significant attention for its potential as a target for innovative antiviral therapies aimed at addressing HCMV-related diseases. In contrast, pUS27 has not been as thoroughly characterized, presenting a potentially promising avenue for antiviral intervention. The relative scarcity of research surrounding pUS27 underscores an exciting opportunity for further exploration, as a deeper understanding of its functions and mechanisms may reveal novel strategies for combating HCMV infections. This review seeks to synthesize recent advancements in our understanding of pUS27, elucidating its biological roles, interactions, and potential implications for therapeutic development. We will also highlight critical gaps in the existing literature that warrant further investigation, underscoring the need for a more comprehensive understanding of this understudied receptor. By delving into the complexities of pUS27, we aim to inspire future research initiatives that could lead to the development of novel antiviral treatments, thereby enhancing our overall understanding of HCMV pathogenesis. Importance: The study of vGPCRs is essential for understanding how viruses like HCMV manipulate host cell signaling and evade immune responses. While pUS28 has been extensively studied due to its broad chemokine binding and signaling activity, its lesser-known homolog, pUS27, warrants closer attention. Likely arising from a gene duplication event, pUS27 shares approximately 31% sequence identity with pUS28 and is conserved across HCMV strains, suggesting an important functional role. By focusing on pUS27, we may uncover shared mechanisms that allow therapies to effectively target both pUS28 and pUS27, potentially leading to more potent antiviral treatments. The implications of studying pUS27 are profound, as it could play a pivotal role in improving our approaches to combating HCMV and enhancing our overall understanding of immune evasion strategies. Full article
Show Figures

Figure 1

Back to TopTop